UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                                 WASHINGTON D.C.

                                   FORM 10-QSB

[X]   Quarterly Report Pursuant to Section 13 or 15(d) of the Securities
      Exchange Act of 1934, For the Quarter Ended September 30, 2005

[_]   Transitional Report Pursuant to Section 13 or 15(d) of the Securities
      Exchange Act of 1934

                          Commission File No. 000-28459

                      ADVANCED PLANT PHARMACEUTICALS, INC.
             (Exact name of Registrant as specified in its charter)

             Delaware                              59-2762023
        -------------------                    -------------------
   (State  of other jurisdiction       (I.R.S. Employer Identification Number)
of  incorporation  or  organization)

                  43 West 33rd Street, New York, New York 10001
                  ---------------------------------------------
                     Address of principal executive offices

        Registrant's telephone number, including area code: 212-695-3334

Indicate by check mark whether the issuer (1) has filed all reports required to
be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the issuer was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes [X] No [_]

As of November 18, 2005, there were issued and outstanding 786,382,298, shares
of Common Stock, $.0007 par value per share.

Transitional Small Business Disclosure Format Yes [_] No [X]

Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act) Yes [_] No [X]


<PAGE>

                      ADVANCED PLANT PHARMACEUTICALS, INC.

                                      INDEX
                                      -----

                                                                        PAGE
PART I.  FINANCIAL INFORMATION                                         NUMBER
         ---------------------                                       ----------

Item 1.  Condensed financial statements (unaudited)

         Condensed Balance sheet as of September 30, 2005                 3

         Condensed Statements of operations for the
           three and nine months ended September 30, 2005
           and 2004                                                       4

         Condensed Statements of cash flows for the
           nine months ended September 30, 2005 and 2004                  5

         Notes to the condensed financial statements                      7

Item 2.  Management's Discussion and Analysis of Financial
           Condition and Results of Operations                            9

Item 3.  Controls and Procedures                                         11

PART II. OTHER INFORMATION                                               12
         ----------------

SIGNATURES                                                               13


                                       2
<PAGE>

                                     PART I

ITEM 1. CONDENSED FINANCIAL STATEMENTS

              ADVANCED PLANT PHARMACEUTICALS, INC. AND SUBSIDIARIES

                           CONSOLIDATED BALANCE SHEETS

<TABLE>
<CAPTION>
                                                                                September 30,    December 31,
                                                                                     2005            2004
                                                                                -------------    ------------
                                                                                  Unaudited
<S>                                                                             <C>              <C>
                                     ASSETS

CURRENT ASSETS
  Cash                                                                          $         560    $      1,045
   Accounts receivable                                                                                    306
   Inventory                                                                            1,014
   Prepaid expenses                                                                     5,000
                                                                                -------------    ------------
         Total Current Assets                                                           6,574           1,351

OFFICE EQUIPMENT, net of accumulated depreciation of $2,662
  and $1,824, respectively                                                              1,691           2,529
OTHER ASSETS
  Goodwill                                                                             10,406          10,406
  Intangible assets, net of impairment losses                                          24,599
  Due from related company                                                              6,250
  Other assets                                                                          7,144           7,144
                                                                                -------------    ------------
                                                                                       50,090          17,550
                                                                                -------------    ------------
         Total Assets                                                           $      56,664    $     21,430
                                                                                =============    ============

                    LIABILITIES AND STOCKHOLDERS' DEFICIENCY

CURRENT LIABILITIES
  Bank overdraft                                                                $       8,146    $      5,111
  Accounts payable                                                                    126,893         167,108
  Accrued expenses                                                                    251,285         568,983
  Accrued expenses - stockholders                                                   1,133,603         901,246
  Due to distributor                                                                                  103,500
  Due to stockholder - asset acquisition                                            1,315,000       1,315,000
  Loans payable - stockholders                                                        321,555         228,796
  Deposits                                                                             96,625
                                                                                -------------    ------------
         Total Current Liabilities                                                  3,253,107       3,289,744

STOCKHOLDERS' DEFICIENCY
  Preferred stock, authorized 10,000,000 shares; $0.0007 par value; 5,000,000
    and 2,500,000 shares issued and outstanding at September 30,
    2005 and December 31, 2004, respectively                                            3,500           1,750
  Common stock, authorized 880,000,000
    shares; $0.0007 par value; 797,157,996 and
    748,157,996 shares issued and outstanding at September 30,
    2005 and December 31, 2004, respectively                                          558,711         523,711
  Additional paid-in capital                                                       14,681,548      14,540,226
  Accumulated deficit                                                             (18,440,202)    (18,334,001)
                                                                                -------------    ------------
  Total Stockholders' Deficiency                                                   (3,196,443)     (3,268,314)
                                                                                -------------    ------------
         Total Liabilities and Stockholders' Deficiency                         $      56,664    $     21,430
                                                                                =============    ============
</TABLE>

                 See accompanying notes to financial statements.


                                       3
<PAGE>

              ADVANCED PLANT PHARMACEUTICALS, INC. AND SUBSIDIARIES

                CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

<TABLE>
<CAPTION>
                                                   For the Three Months Ended        For the Nine Months Ended
                                                          September 30,                    September 30,
                                                 ------------------------------    ------------------------------
                                                      2005             2004             2005             2004
                                                 -------------    -------------    -------------    -------------
<S>                                              <C>              <C>              <C>              <C>
                                                                    Restated                          Restated

REVENUE - SALES                                  $       1,458    $       3,557    $       7,387    $      52,532

COSTS AND EXPENSES
  Cost of goods sold                                       122              719            1,948           30,978
  Selling, general and administrative expenses         351,398          326,760          897,129        1,020,499
  Stock based compensation                              51,907                            52,220
  Stock issued for marketing services                    1,872          187,000          121,572          983,367
  Stock issued for consulting services                   3,343            6,250            9,193        1,336,950
  Depreciation                                             279              249              838              314
                                                 -------------    -------------    -------------    -------------
         Total Costs and Expenses                      408,921          520,978        1,082,900        3,372,108
                                                 -------------    -------------    -------------    -------------

NET OPERATING LOSS                                    (407,463)        (517,421)      (1,075,513)      (3,319,576)

OTHER EXPENSE
  Interest expense                                      (2,042)                           (2,072)
                                                 -------------    -------------    -------------    -------------
         Total Other Expense                            (2,042)                           (2,072)
                                                 -------------    -------------    -------------    -------------

INCOME (LOSS) BEFORE EXTRAORDINARY ITEM               (409,505)        (517,421)      (1,077,585)      (3,319,576)

EXTRAORDINARY ITEM
  Forgiveness of debt (net of income taxes)            638,291                           638,291
                                                 -------------    -------------    -------------    -------------

NET INCOME (LOSS)                                $    (228,786)   $    (517,421)   $    (439,294)   $  (3,319,576)
                                                 =============    =============    =============    =============

NET LOSS PER SHARE OF COMMON STOCK               $        (.00)   $        (.00)   $        (.00)   $        (.01)
                                                 =============    =============    =============    =============

WEIGHTED AVERAGE NUMBER OF COMMON
  SHARES OUTSTANDING                               798,114,518      634,951,712      790,978,509      597,039,441
                                                 =============    =============    =============    =============
</TABLE>

                 See accompanying notes to financial statements.


                                       4
<PAGE>

              ADVANCED PLANT PHARMACEUTICALS, INC. AND SUBSIDIARIES

                CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

<TABLE>
<CAPTION>
                                                            For the Nine Months Ended
                                                                  September 30,
                                                            ------------------------
                                                               2005          2004
                                                            ---------    -----------
                                                                          Restated
<S>                                                         <C>          <C>
CASH FLOWS FROM OPERATING ACTIVITIES
  Net loss                                                  $(439,294)   $(3,319,576)
  Stock issued for services                                   183,165      2,320,317
  Depreciation expense                                            838            195
  Forgiveness of debt income                                 (638,291)
  Changes in assets and liabilities:
    Decrease (increase) in accounts receivable                    306         (1,008)
    (Increase) decrease in inventory                           (1,014)        56,060
    Increase in prepaid expenses                               (5,000)        (1,520)
    Increase in other assets                                                 172,000
    Increase (decrease) in accounts payable                    18,216        (45,551)
    Increase in accrued expenses                              175,162        364,260
    Increase in accrued expenses - stockholders               242,357        146,060
                                                            ---------    -----------
      Net cash used in operating activities                  (463,555)      (308,763)

CASH FLOWS FROM INVESTING ACTIVITIES
  Cash paid for office equipment                                              (3,353)
  Cash paid for intangible assets                              (5,579)
  Due from related parties                                     (6,250)        11,738
                                                            ---------    -----------
      Net cash (used in) provided by investing activities     (11,829)         8,385

CASH FLOWS FROM FINANCING ACTIVITIES
  Increase in bank overdraft                                    3,035          7,071
  Cash acquired in acquisition of subsidiary                                     100
  Loans payable - stockholders' - net                          83,759        (31,093)
  Proceeds from due to related company                                         4,037
  Increase in deposits                                         96,625         10,000
  Proceeds from issuance of common stock                      291,480         45,244
                                                            ---------    -----------

      Net cash provided by financing activities               474,899         35,359
                                                            ---------    -----------

      Net increase (decrease) in cash                            (485)      (265,019)

CASH AT BEGINNING OF PERIOD                                     1,045        265,858
                                                            ---------    -----------

CASH AT END OF PERIOD                                       $     560    $       839
                                                            =========    ===========
</TABLE>

                 See accompanying notes to financial statements.


                                       5
<PAGE>

              ADVANCED PLANT PHARMACEUTICALS, INC AND SUBSIDIARIES.

          CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (CONTINUED)

<TABLE>
<CAPTION>
                                                                           For the Nine Months Ended
                                                                                 September 30,
                                                                            -----------------------
                                                                               2005         2004
                                                                            ---------   -----------
                                                                                         Restated
<S>                                                                         <C>         <C>
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

  NON-CASH INVESTING AND FINANCING ACTIVITIES

    Issuance of common stock for services                                   $ 183,165   $ 2,320,317

    Issuance of preferred stock in payment of loans payable
      to stockholders                                                          10,000

    Issuance of preferred stock in payment of accrued expenses
      to stockholders                                                          10,000

    Issuance of common stock in payment of accrued expenses                    16,500

    Purchase of intangible assets for loan payable to stockholder              19,000

    Issuance of common stock in payment of loan payable
      to stockholder                                                                        500,000

    Assets acquired and liabilities assumed in acquisition of subsidiary:

      Cash acquired                                                                             100
      Goodwill                                                                                9,041
      Accrued expenses                                                                       (8,251)
      Loans payable - stockholders                                                             (890)
</TABLE>

                See accompanying notes to financial statements.


                                       6
<PAGE>

              ADVANCED PLANT PHARMACEUTICALS, INC AND SUBSIDIARIES.

                          NOTES TO FINANCIAL STATEMENTS
                               SEPTEMBER 30, 2005

NOTE A - CONDENSED FINANCIAL STATEMENTS

In the opinion of the Company, the accompanying unaudited condensed financial
statements include all adjustments (consisting only of normal recurring
accruals) which are necessary for a fair presentation of the results for the
periods presented. Certain information and footnote disclosure, normally
included in the financial statements prepared in accordance with generally
accepted accounting principles, have been condensed and omitted. The results of
operations for the nine months ended September 30, 2005 are not indicative of
the results of operations for the year ended December 31, 2005. The condensed
financial statements should be read in conjunction with the Company's financial
statements included in its annual Form 10 KSB for the year ended December 31,
2004.

NOTE B - STOCK WARRANTS

At September 30, 2005, the Company had outstanding warrants to purchase
7,000,000 shares of the Company's common stock at a price of $.03 per share. The
warrants are exercisable and expire at various dates through 2007.

NOTE C - COMMITMENTS AND CONTINGENCIES

The Company has employment agreements with three employees, and a consulting
contract with a key consultant, who are also stockholders of the Company. At
September 30, 2005, the Company has a total liability for accrued salaries and
consulting expense to stockholders of $809,800. There could be certain payroll
tax liabilities owed to the IRS on some of the payments for services to certain
consultants that were paid in prior years, pursuant to these employment
agreements.

NOTE D - RELATED PARTIES STOCK AND ASSET TRANSACTIONS

On January 18, 2005, the Company issued 30,000,000 shares of its common stock
under an S-8 filing with the Securities and Exchange Commission to consultants
at $0.00355 per share. The aggregate remuneration of $106,500 has been treated
as stock issued for marketing services and expensed in the current year.

In connection with a private placement, on January 24, 2005 the Company issued
10,000,000 shares of its common stock at $0.002 per share realizing $20,000.

On February 1, 2005, the Company issued 2,500,000 shares of its preferred stock
at $0.008 per share as payment of $20,000 against loans payable - stockholders
and accrued expenses - stockholders.

On March 5, 2005, Amazing Nutritionals, Inc. ("Amazing") a subsidiary of the
Company, entered into an Agreement of Sale with Nature's Backyard, Inc., whereby
Amazing agreed to buy all intellectual property, permits, patents (granted,
pending, or applied for), trademarks, processes, formulation, exact ingredients,
precise way of manufacturing, and related items of the "Slim Cookie", a product
for weight loss and lowering cholesterol. The purchase price is as follows: (a)
Payment of $1,000 and the issuance of 200,000 shares of common stock on signing
the agreement, (b) 300,000 shares of common stock upon signing and filing of a
provisional patent application by the Company, (c) 100,000 shares of common
stock upon the issuance of a patent by the U.S. Patent and Trademark Office, (d)
payment of $4,000 not more than 60 days from the execution of the Agreement, and
(e) payment of $15,000 within 270 days of the execution of the Agreement. The
Company has not made the required payment and is in default of the agreement.

On April 26, 2005, the Company issued 4,000,000 shares of its common stock under
an S-8 filing with the Securities and Exchange Commission to consultants at
$0.00345 per share. The aggregate remuneration of $13,800 has been treated as
stock issued for marketing services and expensed in the current year.


                                       7
<PAGE>

              ADVANCED PLANT PHARMACEUTICALS, INC AND SUBSIDIARIES.

                    NOTES TO FINANCIAL STATEMENTS (CONTINUED)
                               SEPTEMBER 30, 2005

NOTE D - RELATED PARTIES STOCK AND ASSET TRANSACTIONS (CONTINUED)

On April 26, 2005, the Company issued 5,000,000 shares of its common stock under
an S-8 filing with the Securities and Exchange Commission at $0.00345 per share
as payment for accounts payable in the amount of $16,500.

On July 5, 2005, the Company issued 1,000,000 shares of its common stock at
$0.001872 for services. The aggregate remuneration of $1,872 has been treated as
stock issued for marketing services and expensed in the current year.

NOTE E - FORGIVENESS OF DEBT

The Company obtained releases from numerous companies and individuals indicating
that they were not owed any amounts from the Company. During the three and nine
month periods ended September 30, 2005, the Company recognized Forgiveness of
Debt income in the amount of $638,291 from writing off these liabilities.

NOTE F - GOING CONCERN

As reflected in the accompanying financial statements, the Company has current
liabilities in excess of current assets of $3,246,533, resulting in negative
working capital. Management is presently seeking to raise permanent equity
capital in the capital markets to eliminate negative working capital and provide
working capital. Failure to raise equity capital or secure some other form of
long-term debt arrangement will cause the Company to further increase its
negative working capital deficit. However, there are no assurances that the
Company will succeed in obtaining equity financing or some form of long-term
debt instrument.


                                       8
<PAGE>

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS

BACKGROUND

Advanced Plant Pharmaceuticals, Inc. (the "Company") was incorporated in the
State of Delaware in 1986, under the name Ventra Management, Inc. On July 20,
1994, we amended our Certificate of Incorporation to change our name to Advanced
Plant Pharmaceuticals, Inc.

DESCRIPTION OF BUSINESS

The Company continues to focus on the research and development of plant based
dietary supplements. In July 1999, the Company acquired exclusive rights and
interests to a thirteen-step process, which utilizes virtually all of the
nutrients found in plants to manufacture natural herbal dietary supplements. The
purchase price for the thirteen step process was 12,000,000 shares of common
stock of the Company. The shares were issued on February 13, 2001. Further, the
Company is required to issue an additional 6,000,000 shares of common stock when
marketing of the product commences. The Company intends to use this process to
manufacture products that it hopes to distribute worldwide through various sales
distribution contracts.

On February 28, 2000, the Company entered into an Asset Purchase Agreement with
Dr. Bielory to purchase his various allergy and nasal formulations. This
agreement was approved by the Board of Directors on September 6, 2000. Dr.
Bielory was granted a five year option to purchase an aggregate of 18,000,000
shares of the Company's common stock at an exercise price of $180.00. Dr.
Bielroy exercised an option for 12,000,000 shares in the first quarter of 2001.

Sinusol, being the formulation purchased from Dr. Bielory, is a generalized base
solution for the development of an extensive line of specialty products related
to allergy and sinus conditions. The ingredients include a mixture of gently
pH-balanced essential mineral oils that combat the various symptoms related to
allergies and sinus disorders, including congestions, irritated nasal mucosa and
bacterial and fungal infections. Specialized advanced formulations are being
reviewed for patent submission.

In addition to Sinusol, the Company is also currently marketing its Lo-Chol
product. Lo-Chol's formula is derived from the "whole plant" parts of six
selected plants that work in concert to help tip your lipid balance (good and
bad cholesterol) towards a more normal level. These six plants are
synergistically combined using a proprietary "whole plant technology" (a special
pharmaceutical-grade process) that delivers virtually all the natural
phyto-chemicals and active ingredients in the plants. Unlike almost all other
herbal supplements on the market, Lo-Chol does not contain any extracts.
Instead, it utilizes the entire part of a specific plant that is processed and
standardized to deliver optimum potency and nutritional benefits.

RECENT DEVELOPMENTS

In January 2004, the Company acquired a 44% interest in Amazing Nutritionals,
Inc., a development stage company, whereby APPI sold Amazing all of the rights,
title, patents, trademarks, processes and related items of LHM123 which is a
natural composition for the treatment of senile dementias in consideration for
3,300,000 shares of Amazing's common stock.

In December 2004, the Company acquired a 99% interest in Mazal Plant
Pharmaceuticals, Inc. ("Mazal"), a development stage company, whereby APPI sold
Mazal all of its rights relating to or connected with developing, manufacturing
and distributing of three of its products, plant based compositions designed to
treat elevated cholesterol, leukemia and Alzheimer's disease in consideration
for 7,000,000 shares of Mazal's common stock and a receivable of $50,000.

On June 6, 2005, the Company consummated the transactions contemplated by the
Share Exchange Agreement dated as of May 2005 (the "Share Exchange Agreement")
by and among the Company, Akid Corporation ("Akid") and James B. Wiegand.
Pursuant to the Share Exchange Agreement, the Company sold its entire ownership
interest in 7,000,000 shares of the common stock of Mazal to Akid. In exchange,
Akid agreed to issue to the Company 20,000,000 shares (the "Exchange Shares") of
Akid's common stock. Following the consummation of such share exchange, the
Company holds a majority of the issued and outstanding common shares of Akid,
and Akid holds a majority of the issued and outstanding common shares of Mazal.

Akid issued to the Company 17,500,000 of the Exchange Shares at the closing, and
agreed to issue the remaining 2,500,000 of the Exchange Shares upon increasing
its authorized common stock from 20,000,000 shares to 40,000,000 shares.

RESULTS OF OPERATIONS

SIX MONTHS ENDED SEPTEMBER 30, 2005 COMPARED TO THE SIX MONTHS ENDED SEPTEMBER
30, 2004

REVENUES

Revenues generated during the nine months ended September 30, 2005, aggregated
$7,387, as compared to $52,532 for the nine months ended September 30, 2004. The
decrease of $42,145 in revenues from the comparable period in the prior year is
primarily due to less purchases by our exclusive distributors.


                                       9
<PAGE>

COSTS OF GOODS SOLD

Cost of Goods Sold for the nine months ended September 30, 2005, aggregated
$1,948 as compared to $30,978 for the nine months ended September 30, 2004. The
decrease of $29,030 for the nine months ended September 30, 2005 as compared to
the nine months ended September 30, 2004, was primarily due to the use of
product in connection with clinical trials.

OPERATING EXPENSES

Operating Expenses incurred for the nine months ended September 30, 2005
aggregated $1,080,952 as compared to $3,341,130 for the nine months ended
September 30, 2004, which is a decrease of $2,260,178. This decrease was the
result of a decrease in stock issued for marketing services.

NET LOSS

The net loss was $439,294 for the nine months ended September 30, 2005, as
compared to net loss of $3,319,576 for the nine months ended September 30, 2004,
which represents an decrease in the net loss of $2,880,282. The reason for the
decreased net loss is a result of the reasons described above.

THREE MONTHS ENDED SEPTEMBER 30, 2005 COMPARED TO THE THREE MONTHS ENDED
SEPTEMBER 30, 2004.

REVENUES

Revenues generated during the three months ended September 30, 2005, aggregated
$1,458, as compared to $3,557 for the three months ended September 30, 2004. The
decrease of $2,099 in revenues from the comparable period in the prior year is
primarily due to less purchases by our exclusive distributors.

COSTS OF GOODS SOLD

Cost of Goods Sold for the three months ended September 30, 2005, aggregated
$122 as compared to $719 for the three months ended September 30, 2004. The $597
decrease for the three months ended September 30, 2005, was primarily due to
decreased sales.

OPERATING EXPENSES

Operating Expenses incurred for the three months ended September 30, 2005,
aggregated $408,799 as compared to $520,259 for three months ended September 30,
2004, which is a decrease of $111,460. This decrease was the result of a
decrease in the amount of shares issue for marketing services.

NET LOSS

The net loss was $228,786 for the three months ended September 30, 2005, as
compared to net loss of $517,421 for the three months ended September 30, 2004.
The reason for the increased net loss is a result of the reasons described
above.

LIQUIDITY AND CAPITAL RESOURCES

At September 30, 2005, we had working capital deficit of $3,246,533 as compared
with $3,288,393 at December 31, 2004. The decrease in the working capital
deficit is primarily the result of a slight increase in prepaid expenses and a
decrease in accrued expenses.

We have historically sustained our operations and funded our capital
requirements with the funds received from the sale of our products, loans
received from related parties and the sale of our securities. We will still need
additional investments in order to continue operations. Additional investments
are being sought, but we cannot guarantee that we will be able to obtain such
investments.

Financing transactions may include the issuance of equity or debt securities,
obtaining credit facilities, or other financing mechanisms. However, the trading
price of our common stock and the downturn in the U.S. stock and debt markets
could make it more difficult to obtain financing through the issuance of equity
or debt securities. Even if we are able to raise the funds required, it is
possible that we could incur unexpected costs and expenses, fail to collect
significant amounts owed to us, or experience unexpected cash requirements that
would force us to seek alternative financing. Further, if we issue additional
equity or debt securities, stockholders may experience additional dilution or
the new equity securities may have rights, preferences or privileges senior to
those of existing holders of our common stock. If additional financing is not
available or is not available on acceptable terms, we will have to curtail our
operations again.


                                       10
<PAGE>

CRITICAL ACCOUNTING POLICIES

The preparation of financial statements in conformity with accounting principles
generally accepted in the United States requires management of the Company to
make assumptions, estimates and judgments that affect the amounts reported in
the financial statements, including the notes thereto, and related disclosures
of commitments and contingencies, if any. The Company considers its critical
accounting policies to be those that require the more significant judgments and
estimates in the preparation of the Company's financial statements, including
the following: valuation of inventories and intangible assets, valuation of
stock options and warrants, and valuation of all accrued liabilities including
payroll taxes and other contingent liabilities. Management relies on historical
experience and on other assumptions believed to be reasonable under the
circumstances in making its judgment and estimates. Actual results could differ
materially from those estimates.

ITEM 3 - CONTROLS AND PROCEDURES

As of the end of the period covered by this report, we conducted an evaluation,
under the supervision and with the participation of our chief executive officer
and principal financial officer of our disclosure controls and procedures (as
defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act). Based upon
this evaluation, our chief executive officer and principal financial officer
concluded that our disclosure controls and procedures are effective to ensure
that information required to be disclosed by us in the reports that we file or
submit under the Exchange Act is recorded, processed, summarized and reported,
within the time periods specified in the Commission's rules and forms. There was
no change in our internal controls or in other factors that could affect these
controls during our last fiscal year that has materially affected, or is
reasonably likely to materially affect, our internal control over financial
reporting.


                                       11
<PAGE>

                                     PART II

ITEM 1 - LEGAL PROCEEDINGS

From time to time, the Company is a party to litigation or other legal
proceedings that it considers to be a part of the ordinary course of its
business. The Company is not involved currently in legal proceedings that could
reasonably be expected to have a material adverse effect on its business,
prospects, financial condition or results of operations except as set forth
below. We may become involved in material legal proceedings in the future.

ITEM 2 - CHANGES IN SECURITIES

None.

ITEM 3 - DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None

ITEM 5 - OTHER INFORMATION

None

ITEM 6. - EXHIBITS

31.1 Certification of the Chief Executive Officer and Principal Financial
Officer of Advanced Plant Pharmaceuticals, Inc. pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.

32.1 Certification of the Chief Executive Officer and Principal Financial
Officer of Advanced Plant Pharmaceuticals, Inc. pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.


                                       12
<PAGE>

                                   SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

                                     ADVANCED PLANT PHARMACEUTICALS, INC.

                                     By:/s/ David Lieberman
                                        ----------------------------------------
                                        David Lieberman, Chief Executive Officer
                                        and Principal Financial Officer

Dated: November 21, 2005


                                       13